Brotherhood of the Balloon

02/10/2026

Prostate cancer diagnostics are about to level up. 🚀

Alpenglow Biosciences and Virdx just announced a major, multi-year strategic collaboration to advance AI-enabled prostate cancer diagnostics—bridging radiology and pathology in a way that’s never been done before.

By combining:

🧠 MRI-based biophysics AI
🔬 Whole-tissue 3D pathology
⚡ NVIDIA-accelerated computing

…this partnership aims to improve diagnostic accuracy, reduce unnecessary interventions, and deliver more dignified, non-invasive care for patients.

This is what the future of cancer diagnostics looks like:
better data, faster insights, real impact.

Proud to see innovation like this pushing medicine forward. 💙

Learn more. 👇

Alpenglow Biosciences, a leader in AI-powered 3D pathology, today announced a strategic agreement with Virdx, a biophysics AI company focused on MRI-based ca...

02/09/2026

The tech is the most advanced form of radiation, delivering a targeted energy beam to tumors while sparing healthy tissue surrounding the site.

02/09/2026

👀 SNEAK PEEK: Feb. 2026 BOB Tales 👀

23 years. Millions of men. One big takeaway about PSA screening.

New long-term data from Europe confirms what many have suspected: structured PSA screening saves lives—but how and when you screen matters just as much.

So how do you balance early detection without unnecessary biopsies or overtreatment?

👉 We break it down in this month’s newsletter. COMING SOON to members...

02/06/2026

👀SNEAK PEEK: Feb. 2026 BOB Tales👀

PSA test normal? Prostate cancer could still be hiding.

A new urine test may spot cancer early—even when PSA doesn’t. This could change screening forever.

Get the details. 👇

This urine-based biomarker panel offers a promising sensitive and specific noninvasive diagnostic for PCa with the potential to form the basis for laboratory-developed and in vitro diagnostic assays.

12/26/2025

Merry Christmas to our members and their families! Wishing you all a holiday filled with peace, love, good health, and time with the people who matter most. Thank you for being such a supportive and caring community. ~ Bob and Deb🎄

11/28/2025

Happy Thanksgiving to our members.

We’re grateful for each of you — for your spirit, your willingness to stay informed, and the way so many of you give back through advocacy, education, and support for others. This group reflects strength, generosity, and a shared commitment to helping men make informed choices about their health.

Wishing you and your families a warm, meaningful, and restorative Thanksgiving.

Bob Marckini & Deb Hickey

10/30/2025

AI BREAKTHROUGH IN PROSTATE CANCER DIAGNOSIS:

A new study introduces GleasonXAI, an AI system that helps doctors grade prostate cancer more accurately—and explains WHY it made each decision.

Trained on over 1,000 tissue samples reviewed by top pathologists, this tool could make diagnoses more consistent, transparent, and easier to understand.

Smarter AI isn’t replacing doctors—it’s helping them give men clearer, more confident answers. 💙

*As of now, we strongly recommend getting a second opinion on biopsy slides, since reading pathology slides is still highly subjective—and those results guide every treatment decision.

👇 Here's the study:

An inherently explainable AI trained on 1,015 expert-annotated prostate tissue images achieved strong Gleason pattern segmentation while providing interpretable outputs and addressing interobserver variability in pathology.

10/01/2025

💊 Could a common cholesterol drug help men with advanced prostate cancer live longer?

Researchers analyzed health records from more than HALF A MILLION MEN—making this one of the largest real-world studies to date. The results are striking: men on standard hormone therapy (ADT) who also took statins had better survival rates than those who didn’t.

Metformin, a diabetes drug, didn’t show the same effect on its own. But when combined with statins, the benefit was even stronger.

This finding is important because statins are inexpensive, widely available, and typically prescribed for heart health—not cancer. If confirmed, this could change how doctors approach treatment for men with advanced disease.

View the study: 👇

prostate cancer, androgen deprivation therapy (ADT), Metformin, Impact of Metformin and Statins on Prostate Cancer.

09/30/2025

✨ Hope. 🎯 Precision. ⚡ Speed. Theranostics targets only cancer cells—meaning faster treatment, fewer side effects, and better outcomes for patients who need it most—and it’s transforming cancer care at Loma Linda University Cancer Center. 💙🩺

Loma Linda University Cancer Center is the only facility in the region to offer theranostics, a cutting-edge approach that can allow a patient to learn both their diagnosis and personalized treatment plan in one day.

Unlike traditional cancer treatments that can harm healthy cells, theranostics targets only the cancer itself.

✅ The result? Shorter treatment times and milder side effects.

For prostate cancer patients, this process is especially fast. Radiologist Dr. Eric Peters says, “No other therapy has previously been able to treat certain cancers in this way.”

Learn more about : https://bit.ly/3IoDjEQ

09/25/2025

🚨 A New Era in Cancer Care Begins🚨

Loma Linda University Health, the pioneer of hospital-based proton therapy, is making history once again. They are now equipped to deliver FLASH Proton Therapy—a revolutionary technology that can treat tumors in fractions of a second, sparing healthy tissue and transforming patient experiences.

From treating their first patient in 1990 to now advancing the frontiers of cancer care, LLUH continues to lead the world in innovation, precision, and patient-focused treatment.

This milestone isn’t just about technology—it’s about hope, progress, and the future of cancer therapy. Patients today and generations to come stand to benefit from this leap forward.

🌟 History meets innovation. The future of proton therapy is now.

Loma Linda University Health (LLUH), the institution that created the world's first hospital-based Proton Therapy Treatment Center in 1990, and Mevion Medica...

08/22/2025

👀SNEAK PEEK: October BOB Tales👀

AI is uncovering prostate cancer in tissue samples previously deemed healthy by pathologists! A groundbreaking study from Uppsala University shows AI detected subtle changes in over 80% of samples from men who later developed aggressive cancer.

We'll break it down in our next issue, coming soon!

In the meantime, view the full study to learn how AI is changing the game in diagnostic accuracy! 👇

Diagnostic needle biopsies that miss clinically significant prostate cancer (PCa) often sample benign tissue near hidden cancers. Such benign samples might still display subtle morphological signs of cancer elsewhere in the prostate. This study examined if artificial intelligence (AI) could detect t...

08/19/2025

BIG STRIDES IN PROSTATE CANCER RESEARCH:

Back in 2019, scientists discovered that the NSD2 gene helps prostate cancer spread quickly. Now, researchers have learned that NSD2 may actually fuel the disease from its earliest stages.

Here’s why this matters...

▸NSD2 is found only in cancer cells—not in healthy ones. That makes it an exciting target for new treatments.

▸Lab studies show that shutting down NSD2 (and its partner, NSD1) can stop cancer cells in their tracks while leaving healthy tissue unharmed.

The compound used in these studies isn’t ready for people yet, but the findings bring us one step closer to smarter, more precise therapies. In fact, the FDA recently cleared a different NSD2-targeting drug to begin a Phase 1 trial in men with advanced prostate cancer—an important step forward in bringing this research from the lab to the clinic.

Here's the original study. 👇

https://www.nature.com/articles/s41588-024-01893-6